Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $62.78 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Trump on Xi visit: we get along very well
• SmartKem (SMTK) files for 15.13M share offering by selling stockholders